Management of Uveitis-Related Choroidal Neovascularization: From the Pathogenesis to the Therapy

Table 2

Overview of the studies on the therapy of inflammatory CNV.

Study (year) [reference]	Uveitis type	FU	PDT	Bevacizumab; (median numbers of injections)	Ranibizumab; (median numbers of injections)
Saperstein et al. (2002) [20]	POHS	12	21/25
Spaide et al. (2002) [21]	MC	10	7/7^§
Rogers et al. (2003) [22]	MISC	12	8/9^§
Wachtlin et al. (2003) [23]	MISC	22	17/19
Nessi et al. (2004) [24]	TOXO	3	2/3^§
Leslie et al. (2005) [25]	MISC	11	6/6^§‡
Parodi et al. (2006) [26]	MC	12	6/7
Coco et al. (2007) [27]	PIC	23	5/8^§
Gerth et al. (2006) [28]	MISC	23	7/14^§
Lim et al. (2006) [29]	MISC	12	3/5
Mauget-Faÿsse (2006) [30]	TOXO	25	6/8
Nowilaty and Bouhaimed (2006) [31]	VKH	19	4/6^§‡
Adán et al. (2007) [32]	MISC	7		8/9 (1)
Chan et al. (2007) [33]	PIC	6		4/4 (3)
Schadlu et al. (2008) [34]	POHS	6		26/28 (1.8*); most pts. had PDT
Priyanka et al. (2009) [35]	MISC	15		4/6 (3)^§
Tran et al. (2008) [36]	MISC	6		10/10 (2.5)^§‡
Fine et al. (2009) [37]	MC	6		4/5 (1.5)
Lott et al. (2009) [38]	MISC	7		15/21 (2)^§‡
Parodi et al. (2010) [39]	MC	12	9/13	12/14 (3.8*)
Ehrlich et al. (2010) [40]	MISC	9	4/4^§
Kramer et al. (2010) [41]	MISC	12		10/10 (2)^§
Menezo et al. (2010) [42]	PIC	12			8/9 (1)^§
Arevalo et al. (2011) [43]	MISC	12		21/23 (1)
Carneiro et al. (2011) [44]	MISC	6			4/5 (3)
Cornish et al. (2011) [45]	PIC	12		5/6 (2)	2/3 (4)
Juliàn et al. (2011) [46]	MISC	15		12/15 (4.25^∗)^§‡
Rouvas et al. (2011) [47]	MISC	17			16/16 (2)
Troutbeck et al. (2012) [48]	MC	12			6/7 (3.4*)
Iannetti et al. (2013) [49]	MISC	19		7/8 (1)^§
Mansour et al. (2012) [50]	MISC	36		67/81 (3)
Totals (median no of inj.); Percentual of success			105/134; 78.4%	138/159 (2); 86.8%	36/40 (3); 90.0%

The first column shows the first author name, year of publication, and the reference in square brackets; the second column shows the type of uveitis studied (POHS: presumed ocular histoplasmosis, MC: multifocal choroiditis, MISC: miscellaneous, TOXO: toxoplasmosis, PIC: punctuate inner choroidopathy, and VKH: Vogt-Koyanagi-Harada disease); the third column shows the median follow-up calculated from dataset where not available; in the fourth, fifth, and sixth columns we reported the number of eyes whose VA stabilized or improved with the therapy over the number of eyes treated, respectively, for PDT, IVB, and IVR. Also we indicated the median numbers of injections needed or the mean number* if reported in the study. In the cells ‡indicates more than half patients had immunosuppressive treatment or §for steroid therapy. The last row shows the number of cumulative successes in the eyes treated and the relative percentages. Further statistical analysis was impossible due to the extreme heterogeneity of the studies.